Evidence map›Paper›PMID 24839444›Full record

ArticleInternational journal of rheumatology2014

The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis.

A S Avdeeva, E N Aleksandrova, A A Novikov, A V Smirnov, M V Cherkasova, E L Nasonov

Open access · hybridAbstract read
In one paragraph

Article in International journal of rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

A S AvdeevaNasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 115522, Russia.
E N AleksandrovaNasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 115522, Russia.
A A NovikovNasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 115522, Russia.
A V SmirnovNasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 115522, Russia.
M V CherkasovaNasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 115522, Russia.
E L NasonovNasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 115522, Russia.
VA Nasonova Scientific Research Institute of Rheumatology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective. To make individualised decisions regarding treatment is one of the most important challenges in clinical practise, and identification of sensitive and specific markers of prognosis is an important research question. The main objective of this study was to evaluate relationships between the level of autoantibodies, radiographic changes and laboratory markers of bone, and cartilage destruction. Methods. A total of 114 RA patients were examined. The serum concentration of IgM RF, antibodies to cyclic citrullinated peptide (anti-CCP), modified citrullinated vimentin (anti-MCV), matrix metalloproteinase 3 (MMP-3), and cartilage oligomeric matrix protein (COMP, ng/mL) were measured. The van der Heijde-modified Sharp Score was used to quantify the radiologic changes. Results. Among the patients who were high-positive for anti-MCV, the value of total modified Sharp score (mTSS) (96.5; 66-120) was higher as well as the joint space narrowing (82; 60.5-105.5), and a higher level of MMP-3 was recorded more frequently (56%) in comparison with negative/low-positive patients (57; 31-88, 50; 29-82, 31% resp., P < 0.05). The level of COMP was also higher among patients high-positive for anti-MCV (9.7; 8.1-13.1 and 6.8; 5.4-10.7, resp., P = 0.02). Conclusion. A high positive level of anti-MCV as contrasted with anti-CCP and IgM RF is associated with more pronounced destructive changes in the joints.

Identifiers

PMID24839444
PMCPMC4009265
OpenAlexW2161016955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.